Last reviewed · How we verify
Oxaliplatin;Capecitabine;Bevacizumab
Oxaliplatin, Capecitabine, and Bevacizumab, marketed by Hebei Medical University, are established treatments in the oncology space. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the potential for increased competition as the patent expiration approaches.
At a glance
| Generic name | Oxaliplatin;Capecitabine;Bevacizumab |
|---|---|
| Also known as | Capecitabine Plus Oxaliplatin Other names XELOX. |
| Sponsor | Hebei Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- Pan Tumor Rollover Study (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (PHASE3)
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin;Capecitabine;Bevacizumab CI brief — competitive landscape report
- Oxaliplatin;Capecitabine;Bevacizumab updates RSS · CI watch RSS
- Hebei Medical University portfolio CI